Translation of Angiotensin-Converting Enzyme 2 upon Liver- and Lung-Targeted Delivery of Optimized Chemically Modified mRNA

Abstract

Changes in lifestyle and environmental conditions give rise to an increasing prevalence of liver and lung fibrosis, and both have a poor prognosis. Promising results have been reported for recombinant angiotensin-converting enzyme 2 (ACE2) protein administration in experimental liver and lung fibrosis. However, the full potential of ACE2 may be achieved by localized translation of a membrane-anchored form. For this purpose, we advanced the latest RNA technology for liver- and lung-targeted ACE2 translation. We demonstrated in vitro that transfection with ACE2 chemically modified messenger RNA (cmRNA) leads to robust translation of fully matured, membrane-anchored ACE2 protein. In a second step, we designed eight modified ACE2 cmRNA sequences and identified a lead sequence for in vivo application. Finally, formulation of this ACE2 cmRNA in tailor-made lipidoid nanoparticles and in lipid nanoparticles led to liver- and lung-targeted translation of significant amounts of ACE2 protein, respectively. In summary, we provide evidence that RNA transcript therapy (RTT) is a promising approach for ACE2-based treatment of liver and lung fibrosis to be tested in fibrotic disease models.

Leveraging mRNAs sequences to express SARS-CoV-2 antigens in vivo

“…1). Our results prove the concept of this approach and significantly increase protein production compared to the UTRs reported in the literatures 12,[16][17][18] . Lastly, a series of potential SARS-CoV-2 antigens are visualized via fluorescent imaging in both cell and animal models, which may serve as vaccine candidates for the clinical trials.…”

“…The mRNAs encoding Firefly luciferase were synthesized with these 5' UTRs and were delivered to Hep3B and 293T cells using lipofectamine 3000. The control UTRs include CYBA UTRs (named CYBA) 12 , alpha globin UTRs (named AG) 13 , and modified alpha globin UTRs (AG+G with a complete Kozak sequence and 5AG+G without 3' UTR) 18 . 5' UTR from S27a-44 was better than that from S27a-45 ( Fig.…”

mRNA as novel technology for passive immunotherapy

“…Most if not all groups purified their IVT mRNA before in vivo administration. While some simply precipitated the mRNA [195,227,236], most used commercial purification kits. Only a few researchers applied HPLC purification [188,218,232].…”

ACE2 and pACE2: A Pair of Aces for Pulmonary Arterial Hypertension Treatment?

“…Lung-selective ACE2 delivery to increase local activity of the vasoprotective axis of the RAS would be ideal to circumvent unpredictable immunogenicity and functional modifications in circulation. A chemically modified ACE2 mRNA delivered via lipid nanoparticles offers such an alternative for future consideration (14).…”